CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients

Cytokine

Volumn 63, Issue 2, 2013, Pages 105-112

  Ragab, Dina ^a,b   Laird, Melissa ^a,c   Duffy, Darragh ^a,c   Casrouge, Armanda ^a,c   Mamdouh, Rasha ^b   Abass, Amal ^b   Shenawy, Dina E ^b   Shebl, Abdelhadi M ^d   Elkashef, Wagdi F ^d   Zalata, Khaled R ^d   Kamal, Mostafa ^b,e   Esmat, Gamal ^e,f   Bonnard, Philippe ^g   Fontanet, Arnaud ^a,h   Rafik, Mona ^b   Albert, Matthew L ^a,c,i  

^a INSTITUT PASTEUR   (France)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c INSERM   (France)

^d MANSOURA UNIVERSITY   (Egypt)

^e National Hepatology and Tropical Medicine Research Institute NHTMRI   (Egypt)

^f CAIRO UNIVERSITY   (Egypt)

^g HÔPITAL TENON   (France)

^h Bioinformatique et Chimie Moléculaire   (France)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Chemokine antagonism; Chronic HCVg4; CXCL10; DPPIV; IP10

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; DIPEPTIDYL PEPTIDASE IV; GAMMA INTERFERON INDUCIBLE PROTEIN 10;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EGYPT; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FLOW CYTOMETRY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LIVER BIOPSY; LIVER DISEASE; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADOLESCENT; ADULT; CHEMOKINE CXCL10; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; EGYPT; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INFLAMMATION; LIVER; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; RECEPTORS, CXCR3; YOUNG ADULT;

HEPATITIS C VIRUS;

EID: 84878963455     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.04.016     Document Type: Article

References (22)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011, 17:107-115.
2. Miller F.D., Abu-Raddad L.J. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci USA 2010, 107:14757-14762.
3. Frank C., Mohamed M.K., Strickland G.T., et al. The role of parenteral antichistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000, 355:887-891.
4. Harvey C.E., Post J.J., Palladinetti P., et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukocyte Biol 2003, 74:360-369.
5. Larrubia J., Benito-Martinez S., Calvinho M., Sanz-de-Villalobos E., Parra-Cid T. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastoenterol 2008, 14:7149-7159.
6. Butera D., Marukian S., Iwamaye A.E., et al. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 2005, 106:1175-1182.
7. Diago M., Castellano G., Garcia-Samaniego J., et al. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut 2006, 55:374-379.
8. Lagging M., Romero A.I., Westin J., et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 2006, 44:1617-1625.
9. Reiberger T., Aberle J.H., Kundi M., et al. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection. Antiviral Ther 2008, 13:969-976.
10. Romero A.I., Lagging M., Westin J., et al. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006, 194:895-903.
11. Casrouge A., Decalf J., Ahloulay M., et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest 2011, 121:308-317.
12. Casrouge A., Bisiaux A., Stephen L., et al. Discrimination of agonist and antagonist forms of CXCL10 in biological samples. Clin Exp Immunol 2012, 167:137-148.
13. Bedossa P. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994, 20:15-20.
14. Zeremski M., Petrovic L.M., Chiriboga L., et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 2008, 48:1440-1450.
15. Casrouge A., Decalf J., Ahloulay M., et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest 2011, 121:308-317.
16. Mattern T., Scholz W., Feller A.C., Flad H.D., Ulmer A.J. Expression of CD26 (dipeptidyl peptidase IV) on resting and activated human T-lymphocytes. Scand J Immunol 1991, 33:737-748.
17. Wolf M., Albrecht S., Marki C. Proteolytic processing of chemokines: implications in physiological and pathological conditions. Int J Biochem Cell Biol 2008, 40:1185-1198.
18. Lambeir A.M., Proost P., Durinx C., et al. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem 2001, 276:29839-29845.
19. Ludwig A., Schiemann F., Mentlein R., Lindner B., Brandt E. Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine. J Leukocyte Biol 2002, 72:183-191.
20. Neumiller J.J., Wood L., Campbell R.K. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010, 30:463-484.
21. Negro F. Insulin resistance and HCV: will new knowledge modify clinical management?. J Hepatol 2006, 45:514-519.
22. Romero-Gomez M. Insulin resistance and hepatitis C. World J Gastroenterol 2006, 12:7075-7080.